In-depth interpretation of the latest research on the genome of the three major CNS magazines

With the deepening of research, scientists have made a number of important research results in the study of genomic characteristics. In this article, we have compiled a series of breakthrough researches on CNS's three major journals and genomes in recent years, and learn with you!

[1] Cell: Individualized genome sequencing or accelerated development of individualized therapy

Imagine if you carry a credit card with a genome consisting of 3 billion A, T, C, and G letters, you can immediately help the doctor to determine whether the drug is beneficial or harmful to you by simply swiping the credit card. And this is the goal of US President Barack Obama initially investing $215 million to develop new personalized therapies.

深度解读CNS三大杂志对基因组的最新研究

In a recent research paper published in the international magazine Cell, research from researchers at the University of Pennsylvania has once again advanced the development of individualized therapies; the study began with a name called thiazolidinediones (TZDs). An antidiabetic drug that is very effective in some patients with diabetes (20% to 30%), but has no effect on other patients, and sometimes causes serious side effects.

Therefore, the researchers speculate that some patients will be effective in taking TZDs, while some patients will cause side effects, the key is the mutation caused by small differences in the individual genome region, and the special genomic region can control the opening of genes or Closed, just like the switch of the lamp, and this area is called the gene regulatory region. When the nuclear receptor is adsorbed onto the DNA, the regulatory region will act by opening the gene.

[2]Cell NEJM: Another breakthrough in the Global Cancer Genome Atlas program illustrates the pathogenesis of fatal kidney cancer

Recently, in a research paper published in the international journal The New England Journal of Medicine, scientists from the Cancer Genome Atlas research program conducted two studies on the second common type of kidney cancer. The types were analyzed for molecular characteristics, and this common type of kidney cancer was classified differently.

The annual incidence of papillary renal cell carcinoma in common kidney cancer accounts for 15% to 20%. For a long time, this type of kidney cancer has been classified into type 1 and type 2, but the researchers have initiated nipples. The genetic and molecular causes of renal cell carcinoma are poorly understood, and because of this there has been no effective treatment to help treat papillary renal cell carcinoma.

In the article, the researcher Dr. Hui Shen said that papillary renal cell carcinoma poses a special problem for scientists. In some patients, although the disease does not have any pain, it has spread widely in the kidneys of patients. In other cases, a single lesion may be extremely malignant; in this study, the researchers not only provided clinicians with the clinical research-based data they needed, but also developed new targeted therapies to better The treatment of papillary renal cell carcinoma subtypes provides hope.

[3] Cell: Using genomic big data to develop anticancer drugs

Scientists are beginning to accumulate huge data sets on which genes in cancer are mutated in order to allow for a more systematic approach to achieving " precise medical care ."

In a new study, researchers from the Wellcome Foundation's Sanger Institute, the European Institute of Bioinformatics, and the Dutch Cancer Institute compared genetic mutations in cancer cells and cancer cell lines. Gene mutations are then tested for the response of these cancer cell lines to different therapeutic compounds. By analyzing where these data sets overlap, they can begin to predict which drugs will best resist multiple cancers on a larger scale. The results of the study were published online in the Journal of Cell on July 7, 2016, and the paper titled "A Landscape of Pharmacogenomic Interactions in Cancer."

According to Mathew Garnett, a cancer biologist at the Sanger Institute at the Welkom Foundation, the process we are doing is essentially a discovery process. It begins to give people new ideas: how to make use of it. Specific drugs are targeted to treat specific patient populations. This type of study was not possible a few years ago because we did not sequence enough patient tumors at the time."

Wireless video doorbell

Wireless Video Doorbell,Smart Wireless Video Doorbell Made In China,720P 1080P Wireless Video Doorbell, Wireless Video Doorbell With Batteries,Wireless Video Doorbell Villa

Zhuhai Mingke Electronics Technology Co., Ltd , https://www.zhmkdz-electronics.com